Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Halozyme Names GC and Chief Compliance Officer | Contract Pharma
Breaking News, Promotions & Moves

Halozyme Names GC and Chief Compliance Officer

Leonhardt brings more than 30 years of experience

Harry J. Leonhardt has been appointed senior vice president, general counsel and chief compliance officer, Halozyme Therapeutics, Inc. He will be responsible for all legal, compliance and intellectual property matters and reports to Dr. Helen Torley, president and chief executive officer.

Mr. Leonhardt has more than 30 years of corporate legal, intellectual property, compliance, business development and M&A experience, with an extensive background in the biotechnology sector. He most recently served as senior vice president of Legal and Compliance, and corporate secretary for Amylin Pharmaceuticals, a biotech company acquired by Bristol Myers Squibb in 2012.  

“As Halozyme executes our drug development strategies and prepares for the future commercialization of our oncology pipeline, I am pleased to welcome a biotech veteran of Harry’s caliber to our management team,” said Dr. Torley. “His experience will be invaluable to our team and will help facilitate the continued growth and success of our business.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters